EU panel issues negative opinion on Zevra's arimoclomol for Niemann-Pick disease type C
ZVRA•The European Medicines Agency's CHMP issued a negative opinion on Zevra Therapeutics' arimoclomol application for Niemann-Pick disease type C. The European Commission is expected to make its final decision within 67 days.
1. EU review
The European Medicines Agency's CHMP issued a negative opinion on Zevra Therapeutics' arimoclomol application for Niemann-Pick disease type C. The European Commission is expected to issue its final decision on the marketing authorization application within 67 days. Eligible patients currently receiving arimoclomol will retain support through the global Expanded Access Program, subject to regulatory requirements.
